Akademik Veri Yönetim Sistemi
Retina-Vitreus, cilt.28, sa.1, ss.26-30, 2020 (Scopus)
Purpose: To evaluate the result of topical brinzolamide treatment in patients diagnosed as X-linked juvenile retinoschisis (XLRS). Subjects and Methods: We retrospectively screened files of 16 patients with XLRS diagnosed between January, 2010 and January, 2016 and 16 eyes of 8 patients who were on topical brinzolamide treatment for at least 12 months or more were included to the study. Changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated. Results: Mean age 12.8±4.2 years (range: 6-18 years) and the mean follow-up time was 36.0±24.0 months (range: 12-84 months) in our patients. Median BCVA with Snellen chart was 0.2 (range: 0.1-0.6) and mean CMT was 509.3±124.7 micron (range: 215-646 micron) at the baseline. Topical brinzolamide was prescribed as tid in all patients. Median BCVA was 0.25 (range: 0.1-0.7) and mean CMT was 457.8±135.6 micron (range: 202-714 micron) at the last visit. There was a statistical difference in baseline and final BCVA and CMT (p<0.05). The BCVA improved more than one-order in 9 eyes, unchanged in six eyes and was worsened more than one-order in one eye despite the decrease of CMT. A reduction of at least 20% in CMT was achieved in 4 eyes whereas 10-20% in 4 eyes and below 10% in 5 eyes at the end of follow-up. CMT increase was observed in 3 eyes despite the topical brinzolamide treatment. Conclusion: In patients with XLRS, topical brinzolamide administration may provide some improvement in visual acuity and relative stabilization in central macular thickness.